
Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2025
Description
DelveInsight’s, “Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Cyclin-Dependent Kinase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cyclin-Dependent Kinase Inhibitor: Overview
Cyclin-dependent kinase inhibitor protein (also known as CKIs, CDIs, or CDKIs) is a protein which inhibits the enzyme cycling-dependent kinase (CDK) and Cyclin activity by stopping the cell cycle if there are unfavorable conditions, therefore, acting as tumor suppressors. Cell cycle progression is stopped by Cyclin-dependent kinase inhibitor protein at the G1 phase. CKIs are vital proteins within the control system that point out whether the process of DNA synthesis, mitosis, and cytokines control one another. If a malfunction prevents the successful completion of DNA synthesis during the G1 phase, a signal is sent to delay or stop the progression to the S phase. Cyclin-dependent kinase inhibitor proteins are essential in the regulation of the cell cycle. If cell mutations surpass the cell cycle checkpoints during cell cycle regulation, it can result in various types of cancer. In the cyclin-dependent kinase (CDK) family or CDK, Cyclin, and CKIs, serine/threonine kinases play an integral role in regulating the eukaryotic cell cycle. The structure of CDK2-CyclinA and p27 is determined by crystallography, demonstrating that the inhibitor of p27 stretches at the top of the Cyclin-CDK complex. The amino terminal of p27 has an RXL motif exhibiting a hydrophobic patch of cyclin A. The carboxyl-terminal end of the p27 fragment interacts with the beta sheet of CDKs, causing interference of the structure; p27 slides into the ATP- binding site of CDK2 and inhibits ATP binding.
Cyclin-dependent kinase inhibitor proteins work by inactivating the CDKs by degradation. The typical inactivation mechanism of the CDK/ Cyclin complex is based on binding a CDK inhibitor to the CDK cyclin complex and a partial conformational rotation of the CDK. The cyclin is thus forced to release the T loop and detach from the CDK. Then, the CDK inhibitor initiates a small Helix into the cleft blocking the cleft and blocking the active site of the CDK. Eventually, it releases the ATP out of the aperture of the CDK and deactivates it. Cyclin-dependent kinase inhibitor proteins use ATP as a phosphate contributor to phosphorylate serine and threonine residues.
CDK-inhibitors can be used as an anti-cancer drug by blocking CDK’s and therefore halting the uncontrolled cellular proliferation seen in cancer. Cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.
“Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Cyclin-Dependent Kinase Inhibitor pipeline landscape is provided which includes the disease overview and Cyclin-Dependent Kinase Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Cyclin-Dependent Kinase Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cyclin-Dependent Kinase Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Cyclin-Dependent Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cyclin-Dependent Kinase Inhibitor Emerging Drugs
Further product details are provided in the report……..
Cyclin-Dependent Kinase Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Cyclin-Dependent Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 50+ products under different phases of clinical development like
Cyclin-Dependent Kinase Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III,II, I, preclinical and discovery stage. It also analyses Cyclin-Dependent Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-Dependent Kinase Inhibitor drugs.
Cyclin-Dependent Kinase Inhibitor Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Cyclin-Dependent Kinase Inhibitor: Overview
Cyclin-dependent kinase inhibitor protein (also known as CKIs, CDIs, or CDKIs) is a protein which inhibits the enzyme cycling-dependent kinase (CDK) and Cyclin activity by stopping the cell cycle if there are unfavorable conditions, therefore, acting as tumor suppressors. Cell cycle progression is stopped by Cyclin-dependent kinase inhibitor protein at the G1 phase. CKIs are vital proteins within the control system that point out whether the process of DNA synthesis, mitosis, and cytokines control one another. If a malfunction prevents the successful completion of DNA synthesis during the G1 phase, a signal is sent to delay or stop the progression to the S phase. Cyclin-dependent kinase inhibitor proteins are essential in the regulation of the cell cycle. If cell mutations surpass the cell cycle checkpoints during cell cycle regulation, it can result in various types of cancer. In the cyclin-dependent kinase (CDK) family or CDK, Cyclin, and CKIs, serine/threonine kinases play an integral role in regulating the eukaryotic cell cycle. The structure of CDK2-CyclinA and p27 is determined by crystallography, demonstrating that the inhibitor of p27 stretches at the top of the Cyclin-CDK complex. The amino terminal of p27 has an RXL motif exhibiting a hydrophobic patch of cyclin A. The carboxyl-terminal end of the p27 fragment interacts with the beta sheet of CDKs, causing interference of the structure; p27 slides into the ATP- binding site of CDK2 and inhibits ATP binding.
Cyclin-dependent kinase inhibitor proteins work by inactivating the CDKs by degradation. The typical inactivation mechanism of the CDK/ Cyclin complex is based on binding a CDK inhibitor to the CDK cyclin complex and a partial conformational rotation of the CDK. The cyclin is thus forced to release the T loop and detach from the CDK. Then, the CDK inhibitor initiates a small Helix into the cleft blocking the cleft and blocking the active site of the CDK. Eventually, it releases the ATP out of the aperture of the CDK and deactivates it. Cyclin-dependent kinase inhibitor proteins use ATP as a phosphate contributor to phosphorylate serine and threonine residues.
CDK-inhibitors can be used as an anti-cancer drug by blocking CDK’s and therefore halting the uncontrolled cellular proliferation seen in cancer. Cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.
“Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Cyclin-Dependent Kinase Inhibitor pipeline landscape is provided which includes the disease overview and Cyclin-Dependent Kinase Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Cyclin-Dependent Kinase Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cyclin-Dependent Kinase Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cyclin-Dependent Kinase Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Cyclin-Dependent Kinase Inhibitor.
This segment of the Cyclin-Dependent Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cyclin-Dependent Kinase Inhibitor Emerging Drugs
- Atirmociclib: Pfizer
- BLU-222: Blueprint Medicines
- SY-5609: Syros Pharmaceuticals
- NKT 3447: NiKang Therapeutics
Further product details are provided in the report……..
Cyclin-Dependent Kinase Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Cyclin-Dependent Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cyclin-Dependent Kinase Inhibitor
Phases
DelveInsight’s report covers around 50+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Cyclin-Dependent Kinase Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III,II, I, preclinical and discovery stage. It also analyses Cyclin-Dependent Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-Dependent Kinase Inhibitor drugs.
Cyclin-Dependent Kinase Inhibitor Report Insights
- Cyclin-Dependent Kinase Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cyclin-Dependent Kinase Inhibitor drugs?
- How many Cyclin-Dependent Kinase Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cyclin-Dependent Kinase Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cyclin-Dependent Kinase Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cyclin-Dependent Kinase Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Syros Pharmaceuticals
- Exelixis
- Prelude Therapeutics
- Blueprint Medicines
- Vincerx Pharma
- Carrick Therapeutics
- Tiziana Life Sciences
- Xuanzhu Biopharmaceutical
- Eli Lilly and Company
- Reverie Labs
- Aucentra Therapeutics
- NiKang Therapeutics
- BeiGene
- AstraZeneca
- Sellas Life Sciences Group
- SY-5609
- XL 102
- PRT3645
- BLU 222
- Enitociclib
- CT-7001
- Milciclib
- XZP 3287
- Abemaciclib
- RVL 101
- AU2 94
- NKT 3447
- BGB 43395
- AZD-8421
- SLS 009
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Table of Contents
180 Pages
- Table of Contents
- Introduction
- Executive Summary
- Cyclin-Dependent Kinase Inhibitor : Overview
- Introduction
- Structure
- Function
- Mechanism of action
- CDK as therapeutic target
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Assessment by Product Type
- Assessment by Stage and Product Type
- Cyclin-Dependent Kinase Inhibitor – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Atirmociclib: Pfizer
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- SY-5609: Syros Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Preclinical Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Cyclin-Dependent Kinase Inhibitor-Collaborations Assessment- Licensing / Partnering / Funding
- Cyclin-Dependent Kinase Inhibitor- Unmet Needs
- Cyclin-Dependent Kinase Inhibitor- Market Drivers and Barriers
- Appendix
- *The Table of Contents is not exhaustive; will be provided in the final report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.